ADCT241220P5000
- 0.00
- 0.000.00%
ADC Therapeutics Newsroom
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 31%
ADC Therapeutics SA's (NYSE:ADCT) Institutional Investors Lost 18% Over the Past Week but Have Profited From Longer-term Gains
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript Summary
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
RBC Capital Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Maintains Target Price $8
Express News | ADC Therapeutics SA : Guggenheim Cuts Target Price to $10 From $11
ADC Therapeutics Initiated at Overweight by Stephens & Co.
ADC Therapeutics Analyst Ratings
ADC Therapeutics (ADCT) Receives a Buy From RBC Capital
Stephens Initiates ADC Therapeutics(ADCT.US) With Buy Rating, Announces Target Price $6
ADC Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Loss $-0.28 Per Share
ADC Therapeutics 3Q Rev $18.5M >ADCT
ADC Therapeutics 3Q Loss/Shr 42c >ADCT
Express News | ADC Therapeutics SA: As of September 30, 2024, Cash and Cash Equivalents Were $274.3 Mln
Express News | ADC Therapeutics Q3 Net Income USD -43.969 Million
Press Release: ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting